ATE472334T1 - Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind - Google Patents
Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sindInfo
- Publication number
- ATE472334T1 ATE472334T1 AT05716455T AT05716455T ATE472334T1 AT E472334 T1 ATE472334 T1 AT E472334T1 AT 05716455 T AT05716455 T AT 05716455T AT 05716455 T AT05716455 T AT 05716455T AT E472334 T1 ATE472334 T1 AT E472334T1
- Authority
- AT
- Austria
- Prior art keywords
- modulating
- polypeptide sequences
- viral proteins
- sequences involved
- immunosuppressive effect
- Prior art date
Links
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 3
- 108010067390 Viral Proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102100034353 Integrase Human genes 0.000 abstract 2
- 108010078428 env Gene Products Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04290838 | 2004-03-30 | ||
| PCT/EP2005/003339 WO2005095442A1 (en) | 2004-03-30 | 2005-03-30 | Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE472334T1 true ATE472334T1 (de) | 2010-07-15 |
Family
ID=34896141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05716455T ATE472334T1 (de) | 2004-03-30 | 2005-03-30 | Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8178657B2 (de) |
| EP (1) | EP1732585B1 (de) |
| JP (1) | JP5060284B2 (de) |
| CN (1) | CN1961001B (de) |
| AT (1) | ATE472334T1 (de) |
| AU (1) | AU2005229411B2 (de) |
| BR (1) | BRPI0509497B1 (de) |
| CA (1) | CA2561376C (de) |
| DE (1) | DE602005022056D1 (de) |
| ES (1) | ES2347445T3 (de) |
| IL (1) | IL178205A (de) |
| MX (1) | MXPA06011272A (de) |
| WO (1) | WO2005095442A1 (de) |
| ZA (1) | ZA200608178B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9777044B2 (en) | 2003-05-02 | 2017-10-03 | Centre National De La Recherche Scientifique (Cnrs) | GLUT-1 as a receptor for HTLV envelopes and its uses |
| EP1871391B1 (de) | 2005-03-30 | 2011-12-28 | Viroxis | Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung |
| US20070185025A1 (en) * | 2005-09-11 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Filoviral immunosuppressive peptides and uses thereof |
| US20080299150A1 (en) * | 2007-05-08 | 2008-12-04 | Sankhia Corporation | Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process |
| US8323891B2 (en) * | 2008-08-01 | 2012-12-04 | Claflin University | miRNA triplex formations for the downregulation of viral replication |
| RU2008140688A (ru) * | 2008-10-15 | 2010-04-20 | Михаил Аркадьевич Шурдов (RU) | Иммуносупрессивный пептид |
| CN102326079B (zh) | 2009-01-09 | 2015-04-15 | 国家科研中心 | 新型受体结合配体及其在检测具有生物学益处的细胞中的用途 |
| WO2011092199A1 (en) * | 2010-01-26 | 2011-08-04 | Institut Gustave Roussy | Mutated xmrv env proteins in the immunosuppressive domain |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| WO2012035369A1 (en) * | 2010-09-17 | 2012-03-22 | Centre National De La Recherche Scientifique | Method for the diagnosis and/or prognosis of inflammatory states |
| PL2734230T3 (pl) | 2011-07-20 | 2019-07-31 | Merial Limited | Rekombinowana szczepionka przeciwko wirusowi białaczki kotów zawierająca zoptymalizowany gen otoczki wirusa białaczki kotów |
| JP6415324B2 (ja) * | 2011-12-07 | 2018-10-31 | ヴィロキシ エス．エー．エス．Ｖｉｒｏｘｉｓ Ｓ．Ａ．Ｓ． | レンチウイルスの変異ｅｎｖタンパク質及び薬物としてのその使用 |
| US9636396B2 (en) | 2011-12-07 | 2017-05-02 | Centre National De La Recherche Scientifique | Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties |
| US9974852B2 (en) | 2013-06-07 | 2018-05-22 | Viroxis Sas | Mutated non-primate lentiviral Env proteins and their use as drugs |
| WO2016199674A1 (ja) * | 2015-06-11 | 2016-12-15 | 学校法人慶應義塾 | 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター |
| WO2017054831A1 (en) * | 2015-10-01 | 2017-04-06 | Stemguard A/S | Use of human derived immunosuppressive proteins and peptides as medicaments |
| CA3074088A1 (en) * | 2017-09-01 | 2019-03-07 | Inprother Aps | A vaccine for use in the prophylaxis and/or treatment of a disease |
| JP7344300B2 (ja) | 2018-09-18 | 2023-09-13 | ブイエヌブイ ニューコ インク． | Ａｒｃベースのカプシドおよびその使用 |
| US11129892B1 (en) | 2020-05-18 | 2021-09-28 | Vnv Newco Inc. | Vaccine compositions comprising endogenous Gag polypeptides |
| WO2022152818A1 (en) | 2021-01-13 | 2022-07-21 | Viroxis | Measles-hiv or measles-htlv vaccine |
| WO2024218400A1 (en) | 2023-04-21 | 2024-10-24 | Inprother Aps | Improved expression of surface-displayed antigens |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4822606A (en) | 1986-04-07 | 1989-04-18 | Duke University | Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences |
| ATE128730T1 (de) * | 1988-12-13 | 1995-10-15 | Univ Harvard | Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe. |
| FR2771011B1 (fr) * | 1997-11-17 | 2000-01-28 | Hippocampe | Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale |
| FR2780069B1 (fr) * | 1998-06-23 | 2002-06-28 | Inst Nat Sante Rech Med | Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications |
| JP2003512844A (ja) * | 1999-10-28 | 2003-04-08 | ユニヴェルシテ・ドゥ・ジュネーブ | 多発性硬化症関連スーパー抗原 |
| WO2002047720A2 (en) * | 2000-12-11 | 2002-06-20 | Tufts University | Treatment and prevention of ebv infection and ebv-associated disorders |
| GB0112126D0 (en) | 2001-05-18 | 2001-07-11 | Allergene Inc | Composition |
-
2005
- 2005-03-30 AU AU2005229411A patent/AU2005229411B2/en not_active Ceased
- 2005-03-30 JP JP2007505491A patent/JP5060284B2/ja not_active Expired - Lifetime
- 2005-03-30 MX MXPA06011272A patent/MXPA06011272A/es not_active Application Discontinuation
- 2005-03-30 ZA ZA200608178A patent/ZA200608178B/xx unknown
- 2005-03-30 ES ES05716455T patent/ES2347445T3/es not_active Expired - Lifetime
- 2005-03-30 US US11/547,399 patent/US8178657B2/en active Active
- 2005-03-30 CA CA2561376A patent/CA2561376C/en not_active Expired - Lifetime
- 2005-03-30 WO PCT/EP2005/003339 patent/WO2005095442A1/en active Application Filing
- 2005-03-30 AT AT05716455T patent/ATE472334T1/de not_active IP Right Cessation
- 2005-03-30 DE DE602005022056T patent/DE602005022056D1/de not_active Expired - Lifetime
- 2005-03-30 CN CN2005800161375A patent/CN1961001B/zh not_active Expired - Fee Related
- 2005-03-30 EP EP05716455A patent/EP1732585B1/de not_active Expired - Lifetime
- 2005-03-30 BR BRPI0509497-6A patent/BRPI0509497B1/pt not_active IP Right Cessation
-
2006
- 2006-09-20 IL IL178205A patent/IL178205A/en active IP Right Grant
-
2012
- 2012-02-17 US US13/399,208 patent/US8597657B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1961001B (zh) | 2012-09-05 |
| BRPI0509497A (pt) | 2007-09-11 |
| CA2561376C (en) | 2016-06-21 |
| IL178205A0 (en) | 2006-12-31 |
| EP1732585A1 (de) | 2006-12-20 |
| ZA200608178B (en) | 2008-10-29 |
| JP2008506357A (ja) | 2008-03-06 |
| US20080008683A1 (en) | 2008-01-10 |
| AU2005229411A1 (en) | 2005-10-13 |
| IL178205A (en) | 2015-05-31 |
| DE602005022056D1 (de) | 2010-08-12 |
| EP1732585B1 (de) | 2010-06-30 |
| JP5060284B2 (ja) | 2012-10-31 |
| CA2561376A1 (en) | 2005-10-13 |
| BRPI0509497B1 (pt) | 2022-07-19 |
| WO2005095442A8 (en) | 2006-11-02 |
| MXPA06011272A (es) | 2007-04-17 |
| AU2005229411B2 (en) | 2010-11-18 |
| ES2347445T3 (es) | 2010-10-29 |
| US8597657B2 (en) | 2013-12-03 |
| WO2005095442A1 (en) | 2005-10-13 |
| US20120189647A1 (en) | 2012-07-26 |
| US8178657B2 (en) | 2012-05-15 |
| CN1961001A (zh) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE472334T1 (de) | Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind | |
| PT1685243E (pt) | Linhas celulares aviárias imortalizadas para a produção de vírus | |
| WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| WO2003104418A3 (en) | RECONSTITUTED POLYPEPTIDES | |
| PH12019500596B1 (en) | Recombinant binding proteins and their use | |
| PH12022552935A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| ATE486128T1 (de) | Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine | |
| ATE466080T1 (de) | Formulierungen und verfahren zum denaturieren von proteinen | |
| IL173952A0 (en) | Anti-angiogenic peptides and pharmaceutical compositions based thereon | |
| MX2007007586A (es) | Composiciones de proteinas de virus de gripe y metodos de uso de las mismas. | |
| AR113492A2 (es) | Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| MX2020006671A (es) | Proteinas de fusion. | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| WO2009097014A3 (en) | Therapeutic kinase modulators | |
| ATE542915T1 (de) | Cst-ii-modifzierungen für erhöhte proteinexpression | |
| PH12022553417A1 (en) | Stabilized corona virus spike protein fusion proteins | |
| DE60330680D1 (de) | Transferrin-fusionsproteinbibliotheken | |
| WO2006047728A3 (en) | Bmp gene and fusion protein | |
| WO2006058159A3 (en) | Methods and compositions for the ex vivo high-throughput detection of protein/protein interactions | |
| DK1594991T3 (da) | Fremgangsmåde til fremstilling af DNA-molekyler | |
| WO2008038296A3 (en) | Recombinant calcitonin fused to interleukin-2 | |
| MXPA05008925A (es) | Ciclooxigenasa-3 humana y usos de la misma. | |
| EP1711604A4 (de) | Diabetogene epitope |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |